MARLBOROUGH, Mass., Feb. 19, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025.
Dan Brennan, executive vice president and chief financial officer, Art Butcher, executive vice president and group president, MedSurg and Asia Pacific, and Kenneth Stein, M.D., senior vice president and chief medical officer, will participate in a 30-minute fireside chat with the host analyst at approximately 9:10 a.m. ET. A live webcast and replay of the session will be accessible at htts://investors.bostonscientific.com. The replay will be available approximately one hour following the completion of the event.
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X, formerly Twitter.
CONTACTS:
Chanel Hastings
Media Relations
+1 (508) 382-0288
This email address is being protected from spambots. You need JavaScript enabled to view it.
Jon Monson
Investor Relations
+1 (508) 683-5450
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$97.36 |
Daily Change: | 0.56 0.58 |
Daily Volume: | 2,905,463 |
Market Cap: | US$144.090B |
July 07, 2025 April 23, 2025 March 03, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load